Daily non-political popular news in brief.

Study finds no survival benefit for gastric cancer patients

04-17-2007 · EurekAlert!

A more intensive postoperative chemotherapy regimen for high-risk gastric cancer patients did not improve their survival, according to a randomized controlled trial in the April 18 Journal of the National Cancer Institute.

Keywords: study, survival, benefit, gastric, cancer, patients, patient

« Previous | Next »

Similar news on "Study finds no survival benefit for gastric cancer patients":

Research shows survival benefit for leukemia patients treated with arsenic trioxide
06-04-2007 · EurekAlert!
Through participation in a government-sponsored multi-year study, researchers at the Comprehensive Cancer Center at Wake Forest University have helped confirm that arsenic trioxide -- marketed as Trisenox -- significantly improves patient survival when coupled with standard chemotherapy treatment in newly diagnosed patients with acute promyelocytic leukemia, or APL.
Similar news · Read more »
OHSU researchers: Surgery, radiation gives early survival advantage in bile duct cancer
10-28-2007 · EurekAlert!
Oregon Health & Science University researchers are reporting the discovery of an early survival advantage when a combination of surgery and radiation therapy is used for patients with a rare but deadly bile duct cancer. "Surgery and radiotherapy shows an early response benefit. It shows that the addition of radiation is potentially reasonable for the first-line treatment," said Clifton David Fuller, M.D., Ph.D., principal investigator of the study.
Similar news · Read more »
Study identifies women with breast cancer most likely to benefit from aromatase inhibitor
10-23-2006 · EurekAlert!
While some breast cancer survivors could benefit from adding aromatase inhibitors to the standard five years of tamoxifen, a new study shows the additional therapy should be weighed carefully for each individual. Tthe study's authors say potential improvement in cancer-free survival beyond five years with the added therapy may be less than two percent for most patients.
Similar news · Read more »
Penn's Abramson Cancer Center part of major phase III study for myeloma
11-21-2007 · EurekAlert!
Researchers from the UPenn's Abramson Cancer Center announced today that findings from two international clinical trials show unprecedented survival for patients with myeloma, a cancer the blood-making cells of bone marrow. Findings show that with the oral drug lenalidomide, in combination with dexamethasone, patients significantly improved by all measures where previous treatments had failed -- including a median survival of nearly three years -- the longest median survival known for this difficult to treat patient group.
Similar news · Read more »
Anthracyclines improve survival in HER2-positive breast cancer patients
12-25-2007 · EurekAlert!
Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.
Similar news · Read more »
Early switch to an aromatase inhibitor increases survival
02-12-2007 · EurekAlert!
For breast cancer patients taking tamoxifen, switching to an aromatase inhibitor within three years significantly improves survival rates, according to a new study. The study reveals that the clear survival benefit was also achieved without an increased risk of death from other causes -- a significant risk associated with tamoxifen.
Similar news · Read more »
Study produces conflicting findings on the use of anti-anemia drug in cancer patients
04-16-2007 · EurekAlert!
Results from a phase III drug trial indicate that an anti-anemia drug did not significantly decrease the need for blood transfusions in patients not on chemotherapy, and decreased overall patient survival when compared to placebo, according to researchers from the UCLA Medical Center at the 2007 Annual Meeting of the American Association for Cancer Research.
Similar news · Read more »
No benefit to increasing dose intensity of chemotherapy in osteosarcoma, study finds
01-16-2007 · EurekAlert!
A dose-intensive regimen of the chemotherapy drugs cisplatin and doxorubicin offered no clinical benefit over standard doses of the chemotherapy drugs in patients with a bone cancer called osteosarcoma, according to results from a randomized trial in the Jan. 17 issue of the Journal of the National Cancer Institute. Although the dose-intensive regimen killed tumor cells better than the standard regimen after surgery, survival rates were similar in both groups.
Similar news · Read more »
Personalized diets may offer relief to advanced cancer patients
03-09-2007 · EurekAlert!
Researchers at the University of Alberta studying the effects of chemotherapy and radiation therapy on the senses report that most advanced cancer patients experience unique and persistent taste and smell abnormalities, believed to be a key factor in malnutrition and poor quality of life. Their study suggests that every patient with chemosensory dysfunction has unique symptoms, and a diet tailored to his/her needs would likely improve quality of life.
Similar news · Read more »
Exercise Helps Breast Cancer Patients Avoid Anemia
10-09-2006 · ScienceDaily
Women undergoing radiation treatment for breast cancer benefit from moderate intensity, regular aerobic activity, according to a new study. The study found that exercise improved the oxygen capacity of patients and maintained levels of red blood cells during radiation treatment.
Similar news · Read more »